Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IIT-ATLG-66
- Development stage
- Unknown
- Lead developer
- Neovii Pharmaceuticals
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IIT-ATLG-66 is an anti-T-lymphocyte globulin (ATLG) therapeutic candidate being developed by Neovii Pharmaceuticals for the treatment of Type 1 Diabetes (T1D). As a polyclonal antibody preparation, it is designed to target and deplete T-lymphocytes, which are responsible for the autoimmune destruction of insulin-producing beta cells in the pancreas. By modulating the immune response, IIT-ATLG-66 aims to preserve endogenous insulin production in patients with T1D. The program is currently in Phase 1 clinical development, leveraging Neovii's established expertise in ATLG therapies such as Grafalon.
- Other names
- anti-T-lymphocyte globulinATLG
Beyond the preview
Go deeper on IIT-ATLG-66.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IIT-ATLG-66.